We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

H-CYTE Inc (HCYT) USD0.001

Sell:$0.03204 Buy:$0.03204 Change: $0.00126 (3.78%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.00126 (3.78%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.00126 (3.78%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

H-CYTE, Inc is a hybrid-biopharmaceutical company. The Company is engaged in developing and delivering treatments for patients with chronic respiratory and pulmonary disorders. It focuses on helping people through medical technology and solutions. The Company’s divisions include the Healthcare Medical Biosciences division and the DenerveX medical device division (DenerveX). Its Healthcare Medical Biosciences division includes the Infusion Vertical and the Biologics Vertical. The Infusion Vertical develops and implements treatment options in autologous cellular therapy (PRP-PBMC) to treat chronic lung disorders. It provides oversight and management to the Lung Health Institute (LHI) clinics located in Tampa, Nashville, and Scottsdale. The Biologics Vertical develops biologics. Its DenerveX system is a non-drug alternative system that helps people with chronic back pain. Its LHI targets the symptoms to improve lung health.

Contact details

201 East Kennedy Blvd, Suite 425
United States
+1 (404) 3936989

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$7.01 million
Shares in issue:
163.38 million
Off Exchange
United States
US dollar

Key personnel

  • Raymond Monteleone
    Chairman of the Board
  • Tanya Rhodes
    Interim Chief Executive Officer, Chief Technology Officer
  • Jeremy Daniel
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.